Acid phosphatase has been prepared in an apparently pure state by affinity chromatography from human prostatic tissue. When dissolved in an acidic albumin solution, lyophilized and stored at -20°C for up to 2 years, no timedependent loss of catalytic activity was detectable in the reconstituted material. Accelerated degradation tests also predicted complete stability. A preliminary distribution of the lyophilized preparation to 143 laboratories confirmed its robustness and demonstrated its potential usefulness as a calibrant to unify the results of different methods of measuring acid phosphatase activity.
Prostate-derived acid phosphatase (EC 3.1. 3.2) in serum has continued to be measured as an aid to the diagnosis and monitoring of prostatic cancer throughout the 53 years that have elapsed since this test was first introduced into urological practice. Much effort has been expended on the characterization of the prostate-specific isoenzyme of acid phosphatase and on improving the sensitivity and specificity of methods for its assay, as well as on the study of physiological and pathological factors that influence the activity of the isoenzyme in serum. In spite of this widespread use and attention, the measurement of prostatic acid phosphatase has never completely fulfilled clinical expectations. Two main considerations are probably responsible for this: first, attempts to extend its role beyond its established correlation with the extent and differentiation of cancerous metastases into the detection of disease in situ, attempts which, even with the added specificity and sensitivity of immunoassays have met with only limited success; and, secondly, the lack of a consensus on methodology which has presented clinicians with uninterpretable, unrelatable and even unreliable results.
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The need to attempt to extend the role of prostatic acid phosphatase to the detection of cancer in situ has now been removed by the advent of measurement of prostate-specific antigen which is more sensitive in the detection of localized disease. However, prostatic acid phosphatase has not been entirely superseded in the monitoring of metastatic cancer and this less expensive test continues to be widely used in clinical laboratories throughout the world. Therefore, it remains the duty of clinical chemists to ensure that this collectively large resource is deployed as effectively as possible; i.e., to improve the reliability and comparability of measurements of prostatic acid phosphatase. Stable, well-characterized preparations of prostatic acid phosphatase with known catalytic activity are central to improvement of methodology.
Early attempts to produce reference materials for prostatic acid phosphatase measurement were inhibited by doubts about the stability of the isoenzyme. These doubts have been "shown to be unfounded. We now describe a preparation of purified human prostatic acid phosphatase of predicted and confirmed good stability, with examples of its potential use in harmonizing disparate assay results. 
Protein
Protein was measured by the Lowry method with bovine serum albumin as standard.? by the bicinchoninic acid method;' or by Kjeldahl digestion," or was estimated from absorbance at 280 nm (1 mg/mL acid phosphatase = A 280 1·44 with 10 mm pathlength).'
Extraction of acid phosphatase
Non-cancerous human prostatic tissue was obtained at autopsy from men clinically free from transmissible disease before death and was stored at -18°C until used. Prostatic extract and the final enzyme preparation (before dilution) were negative on testing for anti-HIV antibodies and hepatitis B antigen. Prostatic tissue was homogenized in deionized water (4 mL/g) containing 170 kallikrein inhibitory units/mL aprotinin and 0·01% v/v Tween 80. The residue was re-extracted in the same way. After pooling the two extracts, the yield of acid phosphatase activity was 192 U per g tissue.
Fractionation
Acid phosphatase activity was precipitated between 40 and 7511/0 saturation with ammonium sulphate. This step was mainly useful in reducing the volume of the extract before affinity chromatography; no advantage was found in using a more complicated fractional precipitation procedure. The precipitate was resuspended in citrate buffer, 100 mmol/L, pH 3· 8, and dialysed first against water and then against columnequilibration buffer (sodium acetate, 50 mmol/L, pH 4· 8, containing 50 mmol/L NaCI). L( + )-tartrate was coupled to AH-Sepharose 4B (Pharmacia, Uppsala, Sweden) by the carbodiimide method." The ammonium sulphate fractionated and dialysed prostatic acid phosphatase was applied to a Sepharose-tartrate column (2' 8 ern x 14 cm) and eluted in a single step with a solution of sodium L( + )-tartrate (20 mmol/L) in the column equilibration buffer ( Fig. 1 ). Neither repeated tartrate-affinity chromatography nor chromatography on con A-Sepharose (Pharmacia) significantly increased the specific activity of the isoenzyme recovered from a single tartrate-affinity column.
The purified acid phosphatase was dialysed against acetate buffer, 100 mmol/L, pH 6'0, then diluted into the same buffer to which 30 gil human serum albumin (negative for hepatitis B antigen and anti-HIV antibodies; Blood Products Laboratory, Elstree, UK) had been added." The solution was dispensed into glass ampoules each containing 1 mL solution and lyophilized.
The lyophilization process was based on that described by Campbell. 8, 9 Determination of the minimum temperature at which the solid/liquid phase transition occurs was performed by measuring the change in electrical conductance with temperature. For acid phosphatase a change in the conductance was measured at -33°C. For the primary phase, the ampoules, each filled with a nominal 1· 00 (± O' 1%) mL solution were placed on the shelf, precooled to -40°C, of a Lyomax 2 freeze-drier (Edwards High Vacuum, Crawley, UK). The operating parameters were: condenser temperature -58 to -60°C; chamber pressure I'9xlO-2 to 3·8xlO-2mbar. The shelf temperature was held at -40°C for 90 h then allowed to rise to + 20°C over 20 h and held at this temperature for a further 6 h. The ampoules were then submitted to secondary desiccation by exposure to phosphorus pentoxide in vacuo for 6 days, flushed with nitrogen, sealed and leak tested. Ampoules were stored at -20°C. The residual moisture content was determined by the Karl Fischer method (Mitsubishi CA05 titration meter) and found to be 0·05% (mean for 10 ampoules). Before use, the contents of each ampoule were reconstituted by adding 1. 00 mL of distilled water at room temperature after which the ampoule was left to stand for 2 min before vortex-mixing for 2 s. The ampoules were maintained at 4°C and the contents used not less than I and not more than 5 h from the start of reconstitution.
RESULTS

Purity and identity
The chosen purification scheme (Table 1) achieved a recovery of 53% of the initial catalytic activity of the prostatic extract. Protein content of the purified preparation was estimated as 806 JLg/mL (A 28o ) , 845 JLg/ml (Lowry) and 806 JLg/mL (bicinchoninic acid method). Colorimetric Kjeldahl analysis (corrected for the nitrogen content of amino-sugar residues) indicated a polypeptide content of 710 JLg/mL. On the basis of the average protein concentration found by the first three methods, the specific activity of the purified prostatic acid phosphatase is 680 U/mg protein.
Non-denaturing polyacrylamide-gel electrophoresis of purified prostatic acid phosphatase at pH 4 followed by staining for acid phosphatase activity'? showed activity with the expected 'band 2' mobility, with striations probably corresponding mainly to different degrees of sialylation.!' Traces of activity of 'band 4' acid phosphatase activity, identified by Lam et al. as a non-glycosylated precursor of the secreted band 2 enzyme,'? were detectable. All active zones were inhibited by including L( +)tartrate in the staining solution. After nondenaturing gradient-pore electrophoresis in polyacrylamide gel, two closely-spaced zones of activity were present at M, 100 000 and 91000, of which the zone at M, 100000 was the stronger, plus a weaker active zone at M, 58000. These three zones were also visible with proteinstaining: however, the relative intensities of activity-and protein-staining of the three zones indicated that the specific activity of the lowest molecular-weight zone was much lower than those of the two heavier zones. Denaturation with mercaptoethanol and SDS followed by SDSpolyacrylamide gel electrophoresis yielded two protein-staining zones, the stronger at M, 49000 being accompanied by a weaker zone at M, 45 000. A trace of high molecular-weight material (about M, 330 (00) was also present.
Size-exclusion HPLC of purified acid phosphatase (LKB Ultropac TSK 02000 SW column) both before and after lyophilization yielded single, symmetrical coincident peaks of both protein and catalytic activity, containing 98% of the applied activity, measured in the nonlyophilized sample (Fig. 2 ). Specific activity was constant across the peak within a coefficient of variation of ± 70/0. Neither protein nor catalytic activity was detected in other fractions. In a separate experiment, the peak of acidphosphatase immunoreactivity coincided with the catalytic activity peak ( Fig. 3) . A single protein component absorbing at 214 nm, a wavelength at which the peptide bond absorbs light, was recovered from reversed-phase HPLC on an SOE C 4 column eluted with a gradient of 0-60% acetonitrile in O·08% of trifluoro-acetic acid in water over 50 min.
Lysine was identified as the N-terminal amino acid of purified prostatic acid phosphatase by Stability and homogeneity The purified prostatic acid phosphatase required dilution of the order of 20000-fold to produce a catalytic concentration within the range of the assay methods whose performance it is intended to assess. A target level of activity of about four times the upper reference limit of the methods was chosen, so that the reference material could be used to prepare calibration curves.
Preliminary experiments indicated good stability of acid phosphatase activity in acetate buffer, 100 mmol/L, containing 30 giL human albumin and adjusted to pH 6·0 after addition of albumin, as reported by Duncan et al. ' Citrate buffer (50 mmol/L, pH 5 '6) gave nonlinear recovery of activity on serial dilution. The human albumin preparation contained less than 4· 5 mmol/L citrate at the dilution used, and this concentration was shown to have no effect on the recovery of acid phosphatase activity on dilution. An Arrhenius plot of catalytic activity against temperature was linear over the range of 15°C to 45°C.
The catalytic concentration of acid phosphatase diluted in the acetate-albumin buffer was unaltered after I year's storage at -20°C and this solution was chosen for lyophilization.
Purified prostatic acid phosphatase diluted in albumin-acetate buffer at pH 6·0 was lyophilized in I mL portions in glass ampoules and sealed under nitrogen as described above. The homogeneity of dispensing was tested by reconstituting 20 ampoules from the 'check-weight' series obtained during filling and lyophilization, i.e, ampoules spaced throughout the filling run and used to determine the constancy of the weight of material dispensed before sealing. The contents of 20 further representative ampoules taken from the run were reconstituted and pooled, and the pooled solution was divided into 20 portions. Acid phosphatase activity was determined on each of the checkweight ampoules and on each aliquot of the pool. The order of both types of sample was randomized according to the same random number sequence and check-weight and pool samples were analysed alternately throughout the analytical run. Repeat analyses were made on the following day in a different random order. Analysis of variance (Table 3) 
Fractions containing acid phosphatase activity and protein recovered after size-exclusion HPLC on a TSK G2000 SW column of purified human prostatic acid phosphatase, lyophilized and rehydrated.
Elution was with ammonium acetate, 0·2 mo/lL, pH 5· 5, at a flow-rate ofD: 5 mLlmin; fraction size 0·5 mL. Activity D; Am . ; specific activity (Ux IDOlA) o. 20 22 24 26 28 30 32
Fraction number
Edman degradation followed by ascending twophase thin-layer chromatography on silica gel with detection by quenching of fluorescence excited at 254 nrn. The sequence of the 10 aminoterminal residues found by gas-phase protein sequencing (Jaytee Biosciences Ltd, Canterbury, UK) was Lys-Glu-Leu-Lys-Phe-Val-Thr-Leu-Val-Phe-in agreement with published sequences. 13, 14 Amino acid composition was determined by online hydrolysis, separation and detection (BioMac Ltd, Glasgow, UK) followed by a second analysis to correct for the acetate buffer blank ( Table 2) . When reconstituted with water, the pH of the solution was 6' 2. There was a loss of activity of 9 -50J0 in rehydrated lyophilized samples stored at -20°C compared with the original solution, of which 1·25070 was probably attributable to changes in dilution incurred in lyophilization and rehydration, but there was no subsequent significant change in activity over 12 days at 4°C. Activity in the reconstituted samples was also stable at 20°C during this period: however, there was a 53070 fall in activity at 37°C over 12 days.
The activity recovered on rehydration of ampoules stored at a range of temperatures from -20°C to 56°C was measured at intervals to enable the yearly loss of activity on storage to be predicted." From an early stage the predicted loss of activity was zero at -20°C and less than 0·1070 per year at 4°C. These predictions were confirmed by real-time measurements in which no loss of activity was detectable in ampoules stored for 2 years at -20°C.
The robustness of the lyophilized acid phosphatase preparation was tested by circulating it to 143 of the laboratories which participate in the United Kingdom National External Quality Assessment Scheme (UK NEQAS) in Clinical Chemistry. No attempt was made to classify methods in detail in this preliminary survey. Nevertheless, agreement between 23 laboratories who used 4-nitrophenyl phosphate as substrate at 37°C was good (CV 7 -3070), while in the largest group (75 laboratories) with l-naphthyl phosphate as substrate at 37°C, a group which probably includes greater methodological variation, inter-laboratory CV was 14-3070 ( Table 4) .
One of the potential uses of enzyme reference materials is to unify the results of assays that are similar in principle but differ in minor respects, by' acting as a common calibrator with which unknown samples are compared. A preliminary test of the ability of the purified prostatic acid phosphatase preparation to fulfil this role was made in the UK NEQAS survey by circulating with it a lyophilized serum preparation (Dade Monitrol X, unassayed), which was analysed by participating laboratories in the same analytical batch as the candidate reference preparation. Results obtained for the serum sample were then recalculated as percentages of the values given by the reference preparation. 16 Recalculated mean values from the several method groups (Table 5) show some convergence in the results for total acid phosphatase activity; however, the range of values is 39· 8-47 -0070 of the calibrator value, or 31-5-47-0070 if the thymolphthalein phosphate method group is included. When the more isoenzyme-specific results for tartrate-inhibited activity are considered, the range of recalculated percentages narrows to 39· 5-43 ·6070. TABLE 
Coefficients of variation calculated by one-way and two-way analysis of variance of data from the between-ampoule homogeneity study.
Individual ampoules of lyophilized acid phosphatase were reconstituted and their activities measured separately. The reconstituted contents of20 similar ampoules werepooled and the activities of 20 aliquots of the pool were determined. *These are approximate two-tailed 90% confidence limits; no measure of uncertainty was available for betweensolution components of variance in a two-way analysis. tThe number of individual solutions used to calculate the mean CV. Only solutions for which two replicates were measured could be used to calculate confidence limits. Only solutions for which two replicates were measured on each day could be used in the two-way analysis. tThis component of variance is sometimes termed 'analytical variation' or 'error'. 
Results of circulating the candidate reference preparation ofpurified, lyophilized human prostatic acid phosphatase to laboratories participating in the UK National External Quality Assessment Scheme in Clinical
Chemistry. Data recalculated after exclusion of results more than 2 SD from initial mean 
DISCUSSION
The specific activity of the purified prostatic acid phosphatase is comparable with values previously reported for the purified enzyme, on the basis of a direct experimental comparison of the various methods of measuring catalytic activity (Table 6 ). Further evidence of purity is provided by the HPLC data, and particularly by the agreement of the IO-residue aminoterminal sequence and the amino acid composition with those predicted from cDNA data. The results of denaturing and non-denaturing electrophoresis are in agreement with the proposed dimeric structure of the acid phosphatase molecule: the closely-spaced zones of M, 100 000 and 91 000 may represent isomeric forms!" or slightly differently glycosylated polypeptides. The low activity associated with the 58000 band may indicate that the monomer retains some slight catalytic activity, or it may be due to a small degree of post-separation reassociation into active dimers.
Although acid phosphatase has traditionally been regarded as a particularly labile enzyme, its stability at acid pH has been known for many years and has been confirmed in this study, both during storage of the lyophilized preparation and during normal laboratory use after rehydration. In the preliminary test of the lyophilized preparation's suitability for its intended use in external quality assessment, its performance in the UK NEQAS was as good as, or better than, that of the serum-based materials usually used to assess assay performance. Thus, it should be possible to use it for this purpose without introducing errors due to the instability or inhomogeneity of the survey sample.
The method-dependence of results of catalytic concentration assays in clinical enzymology continues to present problems of interpretation, often restricting data to purely local use. The recommended method approach has had considerable success in reducing the number of methods that are in use for measuring the activities of diagnostically important enzymes and in improving the inter-laboratory compatibility of results.J! Nevertheless, analytical developments continue to increase the number of methods in use, so that the objective of a single, universally-used, assay method for each enzyme is unlikely to be achieved. Attention has therefore been redirected to the possible use of enzyme calibration materials through the use of which the results of methods that differ in detail (though not in principle) can be brought into numerical agreement. The limitations of this approach have been discussed extensively, particularly the need to ensure that the relationship between the calibrating and calibrated methods exhibited by the enzyme calibrator can be assumed (with an acceptable degree of probability) to be the same as that for individual serum samples.P-"
The results of the calibration exercise reported here show the potential value of the reference preparation in bringing into agreement the results of methods which involve the use of two different substrates, with or without a second acceptor substrate, at two different temperatures, and which exhibit minor differences in substrate concentration and pH. However, close agreement between calibrated results is only seen when the several methods have similar analytical specificities. In the present study, incorporation of L( + )-tartrate into assay methods to enable the activity of the inhibitable prostatic (and lysosomal) isoenzyme(s) to be derived by difference significantly increases their specificity for the prostatic isoenzyme, even when the substrate is I-naphthyl phosphate which is known to have a lower reactivity towards acid phosphatase derived from the osteoclast (type 5, macrophage acid phosphatase), the major nonprostatic acid phosphatase in serum. It is somewhat surprising that results obtained with thymolphthalein monophosphate, a substrate claimed to have nearly absolute specificity for prostatic acid phosphatase, do not coincide with those of tartrate-inhibited methods after recalibration.
The ability of the material to compensate for the relatively small difference between 30°and 37°C in assay temperature is not surprising, in view of the linear Arrhenius relationship between activity and temperature observed over a wider range. However, it must be emphasized again that any use of an enzyme calibrator to transfer results between methods must depend on a test of validity with large numbers of individual patients' samples. IS
